NCT02444351

Brief Summary

Nocturnal calf cramps is a common complaint in patients with lumbar spinal stenosis. The purpose of this study is to evaluate the effect of botulinum toxin A injection into the gastrocnemius muscle in lumbar spinal stenosis patients receiving conservative therapy. We will compare pain score, insomnia severity, functional ability, patient satisfaction, and neurophysiological variables change using electrical stimulator between control (conservative management for spinal stenosis) and botox group (conservative management for spinal stenosis plus botox injection into the gastrocnemius muscle).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2015

Completed
16 days until next milestone

First Posted

Study publicly available on registry

May 14, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

June 26, 2015

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2016

Completed
Last Updated

January 11, 2019

Status Verified

January 1, 2017

Enrollment Period

1 year

First QC Date

April 28, 2015

Last Update Submit

January 9, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain score

    A comparison of pain score between control (conservative management for spinal stenosis) and botox group (conservative management for spinal stenosis plus botox injection into the gastrocnemius muscle).

    follow up 2 weeks (14 days) after injection

Secondary Outcomes (1)

  • patient satisfaction questionnaire using 0 to 4 scale

    follow up 3 months after injection

Study Arms (2)

control group

ACTIVE COMPARATOR
Other: no intervention

botox group

EXPERIMENTAL
Drug: botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle

Interventions

ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).

botox group

Patients in the control group will not receive any injection on the gastrocnemius muscle.

control group

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosed lumbar spinal stenosis with MRI finding
  • nocturnal calf cramps symptoms at least once per week

You may not qualify if:

  • electrolyte disorder
  • congenital muscle disease
  • muscle cramps related medication (statins, diuretics, calcium channel blockers, anticonvulsants etc.)
  • cognitive impairments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine

Seoul, 120-752, South Korea

Location

Related Publications (1)

  • Park SJ, Yoon KB, Yoon DM, Kim SH. Botulinum Toxin Treatment for Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial. Arch Phys Med Rehabil. 2017 May;98(5):957-963. doi: 10.1016/j.apmr.2017.01.017. Epub 2017 Feb 14.

MeSH Terms

Interventions

Botulinum Toxins, Type A

Intervention Hierarchy (Ancestors)

Botulinum ToxinsMetalloendopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesMetalloproteasesBacterial ProteinsProteinsAmino Acids, Peptides, and ProteinsBacterial ToxinsToxins, BiologicalBiological Factors

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2015

First Posted

May 14, 2015

Study Start

June 26, 2015

Primary Completion

June 30, 2016

Study Completion

June 30, 2016

Last Updated

January 11, 2019

Record last verified: 2017-01

Locations